Boundless Bio, Inc. (BOLD)
| Market Cap | 56.87M +106.5% |
| Revenue (ttm) | n/a |
| Net Income | -55.50M |
| EPS | -2.46 |
| Shares Out | 22.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 156,469 |
| Open | 2.460 |
| Previous Close | 2.460 |
| Day's Range | 2.390 - 2.535 |
| 52-Week Range | 0.961 - 3.164 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 10, 2026 |
About BOLD
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel ... [Read more]
Financial Performance
Financial StatementsNews
Boundless Bio Quarterly report: Q3 2026
Boundless Bio has published its Q3 2026 quarterly earnings report on November 10, 2026.
Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
- Daphne Karydas appointed as President and Chief Financial Officer - Weston Miller, MD, appointed as Chief Medical Officer - Additional appointments: Nina Hunter, PhD, as Chief Development Officer an...
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer
Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Seni...
Boundless Bio Quarterly report: Q2 2026
Boundless Bio has published its Q2 2026 quarterly earnings report on August 7, 2026.
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Boundless Bio, Serapha Bio to combine in all-stock merger
Boundless Bio (BOLD) and Serapha Bio announced that they have entered into a definitive merger agreement pursuant to which Serapha will combine with Boundless Bio in an all-stock merger. Prior…
Boundless Bio Transcript: M&A announcement
Boundless and Serapha will merge in an all-stock deal, with Boundless shareholders receiving a cash dividend and a minority stake in the new entity. The combined company will focus on advancing SERP-01, a promising gene editing therapy for AATD, and expects strong financial backing through 2029.
Boundless Bio Press release: M&A announcement
Boundless Bio issued a press release on June 23, 2026, disclosing material business information to investors.
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency
Boundless Bio reports Q1 EPS (60c), consensus (56c)
“We are encouraged by the progress of the KOMODO-1 trial,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio (BOLD). “We continue to expand the body of evidence…
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (...
Boundless Bio Quarterly report: Q1 2026
Boundless Bio has published its Q1 2026 quarterly earnings report on May 8, 2026.
Boundless Bio Earnings release: Q1 2026
Boundless Bio released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Boundless Bio Slides: Corporate presentation
Boundless Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Boundless Bio Proxy statement: Proxy filing
Boundless Bio filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Boundless Bio Proxy statement: Proxy filing
Boundless Bio filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Boundless Bio presents preclinical data for BBI-940 therapy at AACR
Boundless Bio (BOLD) presents preclinical data supporting its lead ecDNA-directed therapy, BBI-940, at the American Association for Cancer Research Annual Meeting 2026. Boundless has identified a nove...
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers Findin...
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...
Boundless Bio Transcript: Leerink Global Healthcare Conference 2026
The company is advancing an oral degrader targeting a novel kinesin critical for ecDNA-driven cancers, with a phase I trial underway in select breast cancer subtypes. Strong preclinical data, a robust financial runway, and a disciplined focus on clinical validation underpin its strategy.
Boundless Bio sees cash runway into 2H28
Cash, cash equivalents, and short-term investments totaled $107.6 million as of December 31, 2025. The Company expects its cash to fund operations into the second half of 2028, through the…
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1...
Boundless Bio Earnings release: Q4 2025
Boundless Bio released its Q4 2025 earnings on March 9, 2026, summarizing the period's financial results.
Boundless Bio Annual report: Q4 2025
Boundless Bio has published its Q4 2025 annual report on March 9, 2026.
Boundless Bio Slides: Corporate presentation
Boundless Bio has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.